Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Chemoprophylaxis vaccination: Phase 1 study to explore stage-specific immunity to Plasmodium falciparum in U.S. adults.

Healy SA, Murphy SC, Hume JCC, Shelton L, Kuntz S, Van Voorhis WC, Moodie Z, Metch B, Wang R, Silver-Brace T, Fishbaugher M, Kennedy M, Finney OC, Chaturvedi R, Hobbs CV, Warner-Lubin M, Talley AK, Wong-Madden S, Stuart K, Wald A, Kappe SH, Kublin JG, Duffy PE.

Clin Infect Dis. 2019 Oct 17. pii: ciz1010. doi: 10.1093/cid/ciz1010. [Epub ahead of print]

PMID:
31621832
2.

A Demographic Analysis of Racial/Ethnic Minority Enrollment Into HVTN Preventive Early Phase HIV Vaccine Clinical Trials Conducted in the United States, 2002-2016.

Huamani KF, Metch B, Broder G, Andrasik M.

Public Health Rep. 2019 Jan/Feb;134(1):72-80. doi: 10.1177/0033354918814260. Epub 2018 Dec 5.

3.

Substance use patterns of HVTN phase I clinical trial participants: Enrollment, risk reduction counseling and retention.

Thiam-Diouf A, Metch B, Sharpe C, Mulugeta R, Andrasik MP.

Vaccine. 2018 Feb 21;36(9):1235-1242. doi: 10.1016/j.vaccine.2017.11.032.

4.

Selection of HIV vaccine candidates for concurrent testing in an efficacy trial.

Huang Y, DiazGranados C, Janes H, Huang Y, deCamp AC, Metch B, Grant S, Sanchez B, Phogat S, Koutsoukos M, Kanesa-Thasan N, Bourguignon P, Collard A, Buchbinder S, Tomaras GD, McElrath J, Gray G, Kublin JG, Corey L, Gilbert PB.

Curr Opin Virol. 2016 Apr;17:57-65. doi: 10.1016/j.coviro.2016.01.007. Epub 2016 Jan 29. Review.

5.

Feasibility of Identifying a Female Sex Worker Cohort at High Risk of HIV Infection in the Caribbean for HIV Vaccine Efficacy Trials: Longitudinal Results of HVTN 907.

Deschamps MM, Metch B, Morgan CA, Zorilla CD, Donastorg Y, Swann E, Taina D, Patrice J, Pape WJ; HVTN 907 Study Team.

J Acquir Immune Defic Syndr. 2016 Jan 1;71(1):70-7. doi: 10.1097/QAI.0000000000000796.

6.

Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men.

Moodie Z, Metch B, Bekker LG, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S, Mngadi K, Innes C, Mathebula M, Allen M, Bentley C, Gilbert PB, Robertson M, Kublin J, Corey L, Gray GE.

PLoS One. 2015 Sep 14;10(9):e0137666. doi: 10.1371/journal.pone.0137666. eCollection 2015.

7.

Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.

Huang Y, Follmann D, Nason M, Zhang L, Huang Y, Mehrotra DV, Moodie Z, Metch B, Janes H, Keefer MC, Churchyard G, Robb ML, Fast PE, Duerr A, McElrath MJ, Corey L, Mascola JR, Graham BS, Sobieszczyk ME, Kublin JG, Robertson M, Hammer SM, Gray GE, Buchbinder SP, Gilbert PB.

PLoS One. 2015 Sep 2;10(9):e0136626. doi: 10.1371/journal.pone.0136626. eCollection 2015.

8.

Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.

Gray GE, Moodie Z, Metch B, Gilbert PB, Bekker LG, Churchyard G, Nchabeleng M, Mlisana K, Laher F, Roux S, Mngadi K, Innes C, Mathebula M, Allen M, McElrath MJ, Robertson M, Kublin J, Corey L; HVTN 503/Phambili study team.

Lancet Infect Dis. 2014 May;14(5):388-96. doi: 10.1016/S1473-3099(14)70020-9. Epub 2014 Feb 20.

9.

Recruitment of Caribbean female commercial sex workers at high risk of HIV infection.

Deschamps MM, Zorrilla CD, Morgan CA, Donastorg Y, Metch B, Madenwald T, Joseph P, Severe K, Garced S, Perez M, Escamilia G, Swann E, Pape JW; HVTN 907 Protocol Team.

Rev Panam Salud Publica. 2013 Aug;34(2):92-8.

10.

Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.

Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J, De Rosa S, Carter DK, Rybczyk K, Frank I, Fuchs J, Koblin B, Kim DH, Joseph P, Keefer MC, Baden LR, Eldridge J, Boyer J, Sherwat A, Cardinali M, Allen M, Pensiero M, Butler C, Khan AS, Yan J, Sardesai NY, Kublin JG, Weiner DB; NIAID HIV Vaccine Trials Network.

J Infect Dis. 2013 Sep 1;208(5):818-29. doi: 10.1093/infdis/jit236. Epub 2013 Jul 8.

11.

Risk behavior among women enrolled in a randomized controlled efficacy trial of an adenoviral vector vaccine to prevent HIV acquisition.

Novak RM, Metch B, Buchbinder S, Cabello R, Donastorg Y, Figoroa JP, Abdul-Jauwad H, Joseph P, Koenig E, Metzger D, Sobieszycz M, Tyndall M, Zorilla C.

AIDS. 2013 Jul 17;27(11):1763-70. doi: 10.1097/QAD.0b013e328360c83e. Erratum in: AIDS. 2013 Sep 10;27(14):2321. Adbul-Jauwad, Hend [corrected to Abdul-Jauwad, Hend].

12.

Feasibility of identifying a cohort of US women at high risk for HIV infection for HIV vaccine efficacy trials: longitudinal results of HVTN 906.

Koblin BA, Metch B, Novak RM, Morgan C, Lucy D, Dunbar D, Graham P, Swann E, Madenwald T, Escamilia G, Frank I; HVTN 906 Study Team.

J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):239-44. doi: 10.1097/QAI.0b013e31828ded1a.

13.

Does participation in an HIV vaccine efficacy trial affect risk behaviour in South Africa?

Gray GE, Metch B, Churchyard G, Mlisana K, Nchabeleng M, Allen M, Moodie Z, Kublin J, Bekker LG; HVTN 503 team.

Vaccine. 2013 Apr 12;31(16):2089-96. doi: 10.1016/j.vaccine.2013.01.031. Epub 2013 Jan 29.

14.

Impact of anti-orthopoxvirus neutralizing antibodies induced by a heterologous prime-boost HIV-1 vaccine on insert-specific immune responses.

Walsh SR, Seaman MS, Grandpre LE, Charbonneau C, Yanosick KE, Metch B, Keefer MC, Dolin R, Baden LR.

Vaccine. 2012 Dec 17;31(1):114-9. doi: 10.1016/j.vaccine.2012.10.093. Epub 2012 Nov 7.

15.

Recruitment of urban US women at risk for HIV infection and willingness to participate in future HIV vaccine trials.

Metch B, Frank I, Novak R, Swann E, Metzger D, Morgan C, Lucy D, Dunbar D, Graham P, Madenwald T, Escamilia G, Koblin B.

AIDS Behav. 2013 Feb;17(2):760-72. doi: 10.1007/s10461-012-0351-6.

16.

Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults.

Kalams SA, Parker S, Jin X, Elizaga M, Metch B, Wang M, Hural J, Lubeck M, Eldridge J, Cardinali M, Blattner WA, Sobieszczyk M, Suriyanon V, Kalichman A, Weiner DB, Baden LR; NIAID HIV Vaccine Trials Network.

PLoS One. 2012;7(1):e29231. doi: 10.1371/journal.pone.0029231. Epub 2012 Jan 5.

17.

Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.

Gray GE, Allen M, Moodie Z, Churchyard G, Bekker LG, Nchabeleng M, Mlisana K, Metch B, de Bruyn G, Latka MH, Roux S, Mathebula M, Naicker N, Ducar C, Carter DK, Puren A, Eaton N, McElrath MJ, Robertson M, Corey L, Kublin JG; HVTN 503/Phambili study team.

Lancet Infect Dis. 2011 Jul;11(7):507-15. doi: 10.1016/S1473-3099(11)70098-6. Epub 2011 May 11. Erratum in: Lancet Infect Dis. 2011 Jul;11(7):495.

18.

A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.

Keefer MC, Frey SE, Elizaga M, Metch B, De Rosa SC, Barroso PF, Tomaras G, Cardinali M, Goepfert P, Kalichman A, Philippon V, McElrath MJ, Jin X, Ferrari G, Defawe OD, Mazzara GP, Montefiori D, Pensiero M, Panicali DL, Corey L; NIAID HIV Vaccine Trials Network.

Vaccine. 2011 Feb 24;29(10):1948-58. doi: 10.1016/j.vaccine.2010.12.104. Epub 2011 Jan 7.

19.

Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients.

Cooper CJ, Metch B, Dragavon J, Coombs RW, Baden LR; NIAID HIV Vaccine Trials Network (HVTN) Vaccine-Induced Seropositivity (VISP) Task Force.

JAMA. 2010 Jul 21;304(3):275-83. doi: 10.1001/jama.2010.926.

20.

Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.

Spearman P, Kalams S, Elizaga M, Metch B, Chiu YL, Allen M, Weinhold KJ, Ferrari G, Parker SD, McElrath MJ, Frey SE, Fuchs JD, Keefer MC, Lubeck MD, Egan M, Braun R, Eldridge JH, Haynes BF, Corey L; NIAID HIV Vaccine Trials Network.

Vaccine. 2009 Jan 7;27(2):243-9. doi: 10.1016/j.vaccine.2008.10.051. Epub 2008 Nov 7.

21.

The HVTN protocol 903 vaccine preparedness study: lessons learned in preparation for HIV vaccine efficacy trials.

Djomand G, Metch B, Zorrilla CD, Donastorg Y, Casapia M, Villafana T, Pape J, Figueroa P, Hansen M, Buchbinder S, Beyrer C; 903 Protocol Team.

J Acquir Immune Defic Syndr. 2008 May 1;48(1):82-9. doi: 10.1097/QAI.0b013e31817236ab.

PMID:
18391750
22.

Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120.

Cleghorn F, Pape JW, Schechter M, Bartholomew C, Sanchez J, Jack N, Metch BJ, Hansen M, Allen M, Cao H, Montefiori DC, Tomaras GD, Gurunathan S, Eastman DJ, do Lago RF, Jean S, Lama JR, Lawrence DN, Wright PF; 026 Protocol Team and the NIAID HIV Vaccine Trials Network.

J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):222-30.

PMID:
17693888
23.

Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines.

Montefiori DC, Metch B, McElrath MJ, Self S, Weinhold KJ, Corey L; HIV Vaccine Trials Network.

J Infect Dis. 2004 Dec 1;190(11):1962-9. Epub 2004 Oct 28.

PMID:
15529261
24.

Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation.

Buchbinder SP, Metch B, Holte SE, Scheer S, Coletti A, Vittinghoff E.

J Acquir Immune Defic Syndr. 2004 May 1;36(1):604-12.

PMID:
15097304
25.

Strategies for recruitment to a population-based lung cancer prevention trial: the CARET experience with heavy smokers. Beta-Carotene and Retinol Efficacy Trial.

Goodman GE, Valanis B, Meyskens FL Jr, Williams JH Jr, Metch BJ, Thornquist MD, Omenn GS.

Cancer Epidemiol Biomarkers Prev. 1998 May;7(5):405-12.

27.

Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.

Rivkin SE, Green S, Metch B, Cruz AB, Abeloff MD, Jewell WR, Costanzi JJ, Farrar WB, Minton JP, Osborne CK.

J Clin Oncol. 1994 Oct;12(10):2078-85.

PMID:
7931477
28.

The effect of long-term beta-carotene and vitamin A administration on serum concentrations of alpha-tocopherol.

Goodman GE, Metch BJ, Omenn GS.

Cancer Epidemiol Biomarkers Prev. 1994 Jul-Aug;3(5):429-32.

29.

Phase II evaluation of amonafide in advanced sarcoma: a Southwest Oncology Group study.

Buys SS, Metch B, Balcerzak SP, Neefe JR, Stuckey WJ.

Cancer Invest. 1994;12(4):399-402.

PMID:
8032960
30.

Pitfalls in quality-of-life assessment: lessons from a Southwest Oncology Group breast cancer clinical trial.

Hayden KA, Moinpour CM, Metch B, Feigl P, O'Bryan RM, Green S, Osborne CK.

Oncol Nurs Forum. 1993 Oct;20(9):1415-9.

PMID:
8265446
31.

One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study.

Rivkin SE, Green S, Metch B, Jewell WR, Costanzi JJ, Altman SJ, Minton JP, O'Bryan RM, Osborne CK.

J Clin Oncol. 1993 Sep;11(9):1710-6.

PMID:
8355037
32.

The Carotene and Retinol Efficacy Trial (CARET) to prevent lung cancer in high-risk populations: pilot study with cigarette smokers.

Goodman GE, Omenn GS, Thornquist MD, Lund B, Metch B, Gylys-Colwell I.

Cancer Epidemiol Biomarkers Prev. 1993 Jul-Aug;2(4):389-96.

33.

The Carotene and Retinol Efficacy Trial (CARET) to prevent lung cancer in high-risk populations: pilot study with asbestos-exposed workers.

Omenn GS, Goodman GE, Thornquist MD, Rosenstock L, Barnhart S, Gylys-Colwell I, Metch B, Lund B.

Cancer Epidemiol Biomarkers Prev. 1993 Jul-Aug;2(4):381-7.

34.

Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study.

Budd GT, Metch B, Weiss SA, Weick JK, Fabian C, Stephens RL, Balcerzak SP.

Cancer Chemother Pharmacol. 1993;31 Suppl 2:S213-6.

PMID:
8453701
35.

A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study.

Zidar BL, Metch B, Balcerzak SP, Pierce HI, Militello L, Keppen MD, Berenberg JL.

Cancer. 1992 Nov 15;70(10):2547-51.

PMID:
1423183
36.

Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.

Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, Kish JA, McClure S, VonFeldt E, Williamson SK, et al.

J Clin Oncol. 1992 Aug;10(8):1245-51.

PMID:
1634913
37.

Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: a summary of the Southwest Oncology Group experience.

Hersh EM, Metch BS, Muggia FM, Brown TD, Whitehead RP, Budd GT, Rinehart JJ, Crawford ED, Bonnet JD, Behrens BC.

J Immunother (1991). 1991 Dec;10(6):426-31.

PMID:
1768676
38.

Phase II study of fazarabine in advanced head and neck cancer. A Southwest Oncology Group study.

Kuebler JP, Metch B, Schuller DE, Keppen M, Hynes HE.

Invest New Drugs. 1991 Nov;9(4):373-4. No abstract available.

PMID:
1725172
39.

Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study.

Zalupski M, Metch B, Balcerzak S, Fletcher WS, Chapman R, Bonnet JD, Weiss GR, Ryan J, Benjamin RS, Baker LH.

J Natl Cancer Inst. 1991 Jul 3;83(13):926-32.

PMID:
2067035
40.

Phase II trial of echinomycin in advanced soft tissue sarcomas. A Southwest Oncology Group study.

Taylor SA, Metch B, Balcerzak SP, Hanson KH.

Invest New Drugs. 1990 Nov;8(4):381-3.

PMID:
2084072
41.

Phase II evaluation of recombinant interferon-beta (IFN-beta ser) in patients with diffuse mesothelioma: a Southwest Oncology Group study.

Von Hoff DD, Metch B, Lucas JG, Balcerzak SP, Grunberg SM, Rivkin SE.

J Interferon Res. 1990 Oct;10(5):531-4.

PMID:
2273299
42.

Quality of life assessment in Southwest Oncology Group trials.

Moinpour CM, Hayden KA, Thompson IM, Feigl P, Metch B.

Oncology (Williston Park). 1990 May;4(5):79-84, 89; discussion 104. Review.

PMID:
2143413
43.

High-dose cisplatin for metastatic soft tissue sarcoma.

Budd GT, Metch B, Balcerzak SP, Fletcher WS, Baker LH, Mortimer JE.

Cancer. 1990 Feb 15;65(4):866-9.

PMID:
2297655
44.

Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study.

Rivkin SE, Green S, Metch B, Glucksberg H, Gad-el-Mawla N, Constanzi JJ, Hoogstraten B, Athens J, Maloney T, Osborne CK, et al.

J Clin Oncol. 1989 Sep;7(9):1229-38.

PMID:
2671283
45.

Analysis of treatment failure patterns. A Southwest Oncology Group Study.

Schuller DE, Stein DW, Metch B.

Arch Otolaryngol Head Neck Surg. 1989 Jul;115(7):834-6.

PMID:
2472157
46.

Quality of life end points in cancer clinical trials: review and recommendations.

Moinpour CM, Feigl P, Metch B, Hayden KA, Meyskens FL Jr, Crowley J.

J Natl Cancer Inst. 1989 Apr 5;81(7):485-95. Review.

47.

Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group.

Schuller DE, Metch B, Stein DW, Mattox D, McCracken JD.

Laryngoscope. 1988 Nov;98(11):1205-11.

PMID:
3054373
48.

VP-16 + adriamycin vs. adriamycin alone in advanced adenocarcinoma of the breast, phase II, a randomized trial: a Southwest Oncology Group Study.

Vaughn CB, Green SJ, O'Bryan R, Reed M, Grozea PN, Fletcher WS, Green JB, Metch B, Oishi N.

Med Pediatr Oncol. 1988;16(5):312-9.

PMID:
3054453
49.

Phase II trial of fludarabine phosphate in patients with head and neck cancer: a Southwest Oncology Group Study.

Weiss GB, Metch B, Von Hoff DD, Taylor SA, Saiers JH.

Cancer Treat Rep. 1987 Dec;71(12):1313-4. No abstract available.

PMID:
2446753
50.

Platinum analogs in recurrent and advanced head and neck cancer: a Southwest Oncology Group and Wayne State University Study.

Al-Sarraf M, Metch B, Kish J, Ensley J, Rinehart JJ, Schuller DE, Coltman CA Jr.

Cancer Treat Rep. 1987 Jul-Aug;71(7-8):723-6.

PMID:
3300967

Supplemental Content

Support Center